Kymera Therapeutics, Inc. 8-K

What Happened

• On January 13, 2026, Kymera Therapeutics, Inc. announced in a press release (furnished as Exhibit 99.1 to an 8‑K) a preliminary estimate of approximately $1.6 billion in cash, cash equivalents and marketable securities as of December 31, 2025.
• The company said it has not yet finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2025. The release also outlines Kymera’s key objectives and strategy for 2026 to advance its immunology program portfolio and notes meetings at the 44th Annual J.P. Morgan Healthcare Conference during the week of January 12, 2026.

Key Details

• Preliminary cash, cash equivalents and marketable securities: ~ $1.6 billion (as of Dec 31, 2025).
• Announcement date / filing: Press release issued and 8‑K furnished on January 13, 2026.
• Financial status: Full Q4 and FY2025 results not yet finalized.
• Corporate outreach: Company to meet with participants at the J.P. Morgan Healthcare Conference (week of Jan 12, 2026) and presented 2026 objectives focused on immunology programs.

Why It Matters

• Cash position: A roughly $1.6B cash balance signals material liquidity that can support Kymera’s R&D and clinical programs—important context for investors evaluating runway and funding needs.
• Pending financials: Because the company has not finalized Q4/FY2025 results, investors should treat this as a preliminary liquidity snapshot and look for the upcoming audited/complete financials for a full picture of earnings, revenue and expenses.
• Investor engagement: The JPM conference meetings and the outlined 2026 objectives provide a roadmap for near‑term milestones that could affect program value and investor expectations, but the filing contains no new revenue or earnings figures.